Does Health-Related Quality of Life Improve for Advanced Pancreatic Cancer Patients Who Respond to Gemcitabine? Analysis of a Randomized Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
Authors:
- Hedy L. KindlerHKHedy L. Kindler
- Laura ArcherLALaura Archer
- Ethan BaschEBEthan Basch
- Donna NiedzwieckiDNDonna Niedzwiecki
- Jane WeeksJWJane Weeks
- Deborah SchragDSDeborah Schrag
- 1 February 2012
- journal article
- research article
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 43 (2) , 205-217
Abstract
No abstract availableKeywords
Funding Information
- NCI, National Institutes of Health
This publication has 19 references indexed in Scilit:
- Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome VariablesJournal of Clinical Oncology, 2008
- Quality of life assessment in advanced pancreatic adenocarcinoma: Results from a phase III randomized trialPancreatology, 2006
- EuroQol and survival prediction in terminal cancer patients: a multicenter prospective study in hospice-palliative care unitsSupportive Care in Cancer, 2005
- A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancerAnnals of Oncology, 2005
- Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III TrialJournal of Clinical Oncology, 2005
- US Valuation of the EQ-5D Health StatesMedical Care, 2005
- Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer StudyJournal of Clinical Oncology, 2005
- Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic CancerJournal of Clinical Oncology, 2004
- Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2003
- Interpretation of quality of life changesQuality of Life Research, 1993